🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

A Study to Assess Change in Disease Symptoms in Adult Participants With Advanced Parkinson Disease Using Subcutaneous Foslevodopa/Foscarbidopa in Belgium

Recruitingn/aAges 18 Years - anyAllAbbVie
NCT07382440 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

Parkinson's disease (PD) is a neurological condition, which affects the brain. PD gets worse over time, but how quickly it progresses varies a lot from person to person. Some symptoms of PD are tremors, stiffness, and slowness of movement. This study will assess how effective Foslevodopa/Foscarbidopa is in treating adult participants with advanced Parkinson Disease under routine clinical practice in Belgium. Foslevodopa/Foscarbidopa is an approved drug for the treatment of Parkinson's Disease. Approximately 120 adult participants who are prescribed Foslevodopa/Foscarbidopa by their doctors will be enrolled at 15 sites across Belgium. Participants will receive Foslevodopa/Foscarbidopa subcutaneous infusion as prescribed by their physician. Participants will be followed for up to 18 months. There is expected to be no additional burden for participants in this trial. Participants will at

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria: * Participant diagnosed with Advanced Parkinson's Disease (PD), aged 18 years or older able to provide voluntary informed consent. * Participant evaluated for commercially available continuous subcutaneous Foslevodopa/Foscarbidopa (LDp/CDp) in the hospital at the clinician's discretion as part of his/her routine clinical care and the intention to administer subcutaneous LDp/CDp made prior to and independent of recruitment into the study. Exclusion Criteria: * Participant participating in an interventional research study (not including noninterventional studies) during the administration of LDp/CDp. * Participant evaluated for commercially available continuous subcutaneous LD/CDp outside of the hospital.
💊

What it tests

  • Not listed
📍

Where

12 sites
Imelda Ziekenhuis /ID# 279436
Bonheiden, Belgium
Universitair Ziekenhuis Antwerpen /ID# 279434
Edegem, Belgium
Chu Tivoli /ID# 279455
La Louvière, Belgium
Centre Hospitalier De Wallonie Picarde - Site Notre Dame /ID# 279452
Tournai, Belgium
Jessa Ziekenhuis - Campus Virga Jesse /ID# 279454
Hasselt, Belgium
AZ Sint-Lucas /ID# 279453
Ghent, Belgium
UZ Gent /ID# 279433
Ghent, Belgium
Universitair Ziekenhuis Leuven /ID# 279439
Leuven, Belgium

…and 4 more on ClinicalTrials.gov.

🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy